BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wijaya I, Andhika R, Huang I, Purwiga A, Budiman KY, Bashari MH, Reniarti L, Roesli RMA. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis. Clin Epidemiol Glob Health 2021;11:100755. [PMID: 33969237 DOI: 10.1016/j.cegh.2021.100755] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Hasan S, Awasthi P, Malik S, Dwivedi M. Immunotherapeutic strategies to induce inflection in the immune response: therapy for cancer and COVID-19. Biotechnology and Genetic Engineering Reviews 2022. [DOI: 10.1080/02648725.2022.2147661] [Reference Citation Analysis]
2 Nazerian Y, Ghasemi M, Yassaghi Y, Nazerian A, Mahmoud Hashemi S. Role of SARS-CoV-2-induced Cytokine Storm in Multi-Organ Failure: Molecular Pathways and Potential Therapeutic Options. International Immunopharmacology 2022. [DOI: 10.1016/j.intimp.2022.109428] [Reference Citation Analysis]
3 Manoharan S, Ying LY. Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis. Respir Med 2022;202:106986. [PMID: 36150282 DOI: 10.1016/j.rmed.2022.106986] [Reference Citation Analysis]
4 Marcec R, Dodig VM, Radanovic I, Likic R. Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID-19 patients: A systematic review and meta-analysis. Rev Med Virol 2022;:e2397. [PMID: 36097650 DOI: 10.1002/rmv.2397] [Reference Citation Analysis]
5 Ezeonwumelu IJ, García-vidal E, Felip E, Puertas MC, Oriol-tordera B, Gutiérrez-chamorro L, Gohr A, Ruiz-riol M, Massanella M, Clotet B, Martinez-picado J, Badia R, Riveira-muñoz E, Ballana E. IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation. Front Immunol 2022;13:1001068. [DOI: 10.3389/fimmu.2022.1001068] [Reference Citation Analysis]
6 Saha C, Harrison C. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib. Expert Rev Hematol 2022. [PMID: 35787092 DOI: 10.1080/17474086.2022.2098105] [Reference Citation Analysis]
7 Levy G, Guglielmelli P, Langmuir P, Constantinescu S. JAK inhibitors and COVID-19. J Immunother Cancer 2022;10:e002838. [PMID: 35459733 DOI: 10.1136/jitc-2021-002838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tolomeo M, Cavalli A, Cascio A. STAT1 and Its Crucial Role in the Control of Viral Infections. Int J Mol Sci 2022;23:4095. [PMID: 35456913 DOI: 10.3390/ijms23084095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
9 Eikelboom J, Rangarajan S, Jolly SS, Belley-Cote EP, Whitlock R, Beresh H, Lewis G, Xu L, Chan N, Bangdiwala S, Diaz R, Orlandini A, Hassany M, Tarhuni WM, Yusufali AM, Sharma SK, Konstsevaya A, Jaramillo PL, Avezum A, Dans AL, Wasserman S, Camilo F, Kazmi K, Pais P, Xavier D, Lopes RD, Berwanger O, Nkeshimana M, Harper W, Loeb M, Choudhri S, Farkouh ME, Bosch J, Anand SS, Yusuf S. The Anti-Coronavirus Therapy (ACT) trials: design, baseline characteristics, and challenges. CJC Open 2022. [PMID: 35252829 DOI: 10.1016/j.cjco.2022.02.010] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Zhang X, Shang L, Fan G, Gu X, Xu J, Wang Y, Huang L, Cao B. The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:800492. [PMID: 35155477 DOI: 10.3389/fmed.2021.800492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
11 Fernández-cruz A, Puyuelo A, Núñez Martín-buitrago L, Sánchez-chica E, Díaz-pedroche C, Ayala R, Lizasoain M, Duarte R, Lumbreras C, Antonio Vargas J. Higher mortality of hospitalized hematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: an age-matched cohorts study. Clinical Infection in Practice 2022. [DOI: 10.1016/j.clinpr.2022.100137] [Reference Citation Analysis]
12 Lin Z, Niu J, Xu Y, Qin L, Ding J, Zhou L. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis. J Med Virol 2021. [PMID: 34846766 DOI: 10.1002/jmv.27482] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
13 Ezeonwumelu IJ, Garcia-Vidal E, Ballana E. JAK-STAT Pathway: A Novel Target to Tackle Viral Infections. Viruses 2021;13:2379. [PMID: 34960648 DOI: 10.3390/v13122379] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
14 Masiá M, Padilla S, García JA, García-Abellán J, Navarro A, Guillén L, Telenti G, Mascarell P, Botella Á, Gutiérrez F. Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19. Front Med (Lausanne) 2021;8:749657. [PMID: 34820393 DOI: 10.3389/fmed.2021.749657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
15 Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021;6:402. [PMID: 34824210 DOI: 10.1038/s41392-021-00791-1] [Cited by in Crossref: 73] [Cited by in F6Publishing: 91] [Article Influence: 73.0] [Reference Citation Analysis]
16 Lan SH, Wang CK, Chang SP, Lu LC, Hung SH, Lin WT. Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34743661 DOI: 10.1080/14787210.2022.2004120] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
17 Rincon-Arevalo H, Aue A, Ritter J, Szelinski F, Khadzhynov D, Zickler D, Stefanski L, Lino AC, Körper S, Eckardt KU, Schrezenmeier H, Dörner T, Schrezenmeier EV. Altered increase in STAT1 expression and phosphorylation in severe COVID-19. Eur J Immunol 2021. [PMID: 34676541 DOI: 10.1002/eji.202149575] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
18 Patoulias D, Doumas M, Papadopoulos C, Karagiannis A. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol 2021;40:4671-4. [PMID: 34431004 DOI: 10.1007/s10067-021-05884-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
19 Rincon-arevalo H, Aue A, Ritter J, Szelinski F, Khadzhynov D, Zickler D, Stefanski L, Lino AC, Körper S, Eckardt K, Schrezenmeier H, Dörner T, Schrezenmeier EV. Altered increase in STAT1 expression and phosphorylation in severe COVID-19.. [DOI: 10.1101/2021.08.13.21262006] [Reference Citation Analysis]
20 Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, Spadea A, Pontone M, Di Martino S, Laquintana V, La Malfa A, Di Domenico EG, Di Bella O, Falzone G, Ensoli F, Vujovic B, Morrone A, Ciliberto G, Mengarelli A. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. J Hematol Oncol 2021;14:119. [PMID: 34325728 DOI: 10.1186/s13045-021-01130-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 25.0] [Reference Citation Analysis]